Memantine Market GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2018-2026 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Memantine Market – Overview Increasing number of pipeline studies for use of memantine are expected to boost growth of the memantine market. For instance, in September 2016, Lille University Hospital started phase I clinical study for assessing the effects of memantine on cognitive behavior of patients associated with Alzheimer’s disease. The study is estimated to be completed by February 2019. Furthermore, Suven Life Sciences Limited is undergoing phase II clinical study for the comparative study on safety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl for treating moderate Alzheimer’s disease. The study was started in September 2015 and is expected to be completed in May 2019. Increasing number of expired patents of drugs is a major factor hindering growth of the global memantine market. For instance, according Merz Pharmaceuticals, a Germany-based company, in October 2018, overall licensing income during patented period for memantine decreased due to expiration of patent protection in a majority of markets. For instance, according to Merz Pharmaceuticals, the U.S. licensing income for memantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34 million in year 2016. © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Memantine Market : Regional Analysis North America is expected to hold dominant position in the global memantine market, owing to increasing number of generic versions of memantine in the U.S. market. For instance, in February 2018, Lupin Limited announced the launch of its Memantine Hydrochloride Extended-Release Capsules in the U.S. market. The capsules are available in 7mg, 14mg, 21mg, and 28mg, for which company has received an approval from the U.S. FDA. These are indicated for the treatment of moderate to severe dementia of the Alzheimer’s disease. Furthermore, Asia Pacific is expected to witness significant growth in the global memantine market, owing to increasing focus of key players in manufacturing memantine tablets. For instance, in October 2018, Dr. Reddy’s Laboratories launched memantine hydrochloride tablets in the Indian market. They are available in 5mg and 10mg, equivalent to generic version of Namenda tablets, which were already available in the U.S. market in July 2015. Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2255 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Memantine Market: Key Players ● Merz Pharmaceuticals ● Lupin Limited ● Allergan ● Novartis AG ● Daiichi Sankyo Company ● Ono Pharmaceutical ● Eisai View this report @ https://www.coherentmarketinsights.com/ongoing-insight/memantine-market-2255 © Coherent market Insights. All Rights Reserved ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES INDUSTRY ANALYSIS CUSTOMIZED RESEARCH SYNDICATED RESEARCH MARKET INTELLIGENCE SERVICES CONSULT STUDIES COUNTRY SPECIFIC STUDIES © Coherent market Insights. All Rights Reserved ABOUT COHERENT MARKET INSIGHTS SECTOR COVERAGE Healthcare CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL IMAGING PHARMACEUTICAL MEDICAL DEVICES Chemicals & Materials Bulk Chemicals Advanced Materials Speciality and Fine Chemicals Green Chemicals Food Ingredients © Coherent market Insights. All Rights Reserved Cosmetic Ingredients Polymers & Resins ABOUT COHERENT MARKET INSIGHTS KEY STATS RESEARCH SOLUTIONS FEASIBILITY STUDIES GLOBAL REPORTS 100+ Insights Published Per Year 150+ Consulting Projects Till Date 125+ Clients Worldwide Per Year 110+ COUNTRY ANALYSIS CONSULT PROJECTS SURVEY RESEARC H EXCEL FORECAST DATABASE CUSTOMIZED SOLUTIONS COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved To k no w mor e abo ut us , v is it o ur w eb site: w ww.coh er en tmark etins ig hts.com THANK YOU © Coherent market Insights. All Rights Reserved F or s ales q ueries o r new top ics email u s o n : s ales@coh er en tmark etins ig hts .co m Fo r o th er q uer ies co n tact: Mr. Sh ah ( Man ag er - Bus iness D ev elo pment) Co herent Mark et Ins ig hts s ales@coh er en tmark etins ig hts .co m +1 -2 06 -7 0 1- 67 02
The drug received European marketing approval in 2002 and the U.S. Food and Drug Administration (U.S FDA) approval in 2003. The generic versions of the drugs are available since 2015. Memantine aids in treatment of moderate to severe dementia associated with Alzheimer's disease.
© Copyright 2024 Paperzz
